It is well established that glutamatergic neurotransmission plays an essential role in learning and memory. Previous studies indicate that glutamate dynamics shift with Alzheimer's disease (AD) progression, contributing to negative cognitive outcomes.
Objective
In this study, we characterized hippocampal glutamatergic signaling with age and disease progression in a knock-in mouse model of AD (APPNL-F/NL--F).
Methods
At 2–4 and 18+ months old, male and female APPNL/NL, APPNL-F/NL-F, and C57BL/6 mice underwent cognitive assessment using Morris water maze (MWM) and Novel Object Recognition (NOR). Then, basal and 70 mM KCl stimulus-evoked glutamate release was measured in the dentate gyrus (DG), CA3, and CA1 regions of the hippocampus using a glutamate-selective microelectrode in anesthetized mice.
Results
Glutamate recordings support elevated stimulus-evoked glutamate release in the DG and CA3 of young APPNL-F/NL-F male mice that declined with age compared to age-matched control mice. Young female APPNL-F/NL-F mice exhibited increased glutamate clearance in the CA1 that slowed with age compared to age-matched control mice. Male and female APPNL-F/NL-F mice exhibited decreased CA1 basal glutamate levels, while males also showed depletion in the CA3. Cognitive assessment demonstrated impaired spatial cognition in aged male and female APPNL-F/NL-F mice, but only aged females displayed recognition memory deficits compared to age-matched control mice.
Conclusions
These findings confirm a sex-dependent hyper-to-hypoactivation glutamatergic paradigm in APPNL-F/NL-F mice. Further, data illustrate a sexually dimorphic biological aging process resulting in a more severe cognitive phenotype for female APPNL-F/NL-F mice than their male counterparts. Research outcomes mirror that of human AD pathology and provide further evidence of divergent AD pathogenesis between sexes.
McEnteeWJCrookTH. Glutamate: its role in learning, memory, and the aging brain. Psychopharmacology (Berl)1993; 111: 391–401.
3.
SegoviaGPorrasADel ArcoA, et al.Glutamatergic neurotransmission in aging: a critical perspective. Mech Ageing Dev2001; 122: 1–29.
4.
CoxMFHascupERBartkeA, et al.Friend or foe? Defining the role of glutamate in aging and Alzheimer’s disease. Front Aging2022; 3: 65.
5.
GasiorowskaAWydrychMDrapichP, et al.The biology and pathobiology of glutamatergic, cholinergic, and dopaminergic signaling in the aging brain. Front Aging Neurosci2021; 13: 391.
6.
LewerenzJMaherP. Chronic glutamate toxicity in neurodegenerative diseases-what is the evidence?Front Neurosci2015; 9: 469.
7.
HuijbersWMorminoECSchultzAP, et al.Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain2015; 138: 1023–1035.
8.
HuijbersWSchultzAPPappKV, et al.Tau accumulation in clinically normal older adults is associated with hippocampal hyperactivity. J Neurosci2019; 39: 548–556.
9.
GhatakSDolatabadiNTrudlerD, et al.Mechanisms of hyperexcitability in Alzheimer’s disease hiPSC-derived neurons and cerebral organoids vs. Isogenic control. Elife2019; 8: e50333.
10.
SokolowSLuuSHNandyK, et al.Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer’s disease cortex. Neurobiol Dis2012; 45: 381–387.
11.
KobayashiENakanoMKubotaK, et al.Activated forms of astrocytes with higher GLT-1 expression are associated with cognitive normal subjects with Alzheimer pathology in human brain. Sci Rep2018; 8: 1712.
12.
ScottHAGebhardtFMMitrovicAD, et al.Glutamate transporter variants reduce glutamate uptake in Alzheimer’s disease. Neurobiol Aging2011; 32: 553.e1–553.e11.
13.
DanyszWParsonsCG. Alzheimer’s disease, β-amyloid, glutamate, NMDA receptors and memantine–searching for the connections. Br J Pharmacol2012; 167: 324–352.
14.
FayedNModregoPJRojas-SalinasG, et al.Brain glutamate levels are decreased in Alzheimer’s disease: a magnetic resonance spectroscopy study. Am J Alzheimers Dis Other Demen2011; 26: 450–456.
15.
Rodriguez-PerdigonMTorderaRMGil-BeaFJ, et al.Down-regulation of glutamatergic terminals (VGLUT1) driven by Aβ in Alzheimer’s disease. Hippocampus2016; 26: 1303–1312.
16.
HascupKNFindleyCASimeLN, et al.Hippocampal alterations in glutamatergic signaling during amyloid progression in AβPP/PS1 mice. Sci Rep2020; 10: 14503.
17.
FindleyCABartkeAHascupKN, et al.Amyloid beta-related alterations to glutamate signaling dynamics during Alzheimer’s disease progression. ASN Neuro2019; 11: 1759091419855541.
18.
OlneyJWWozniakDFFarberNB. Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. Arch Neurol1997; 54: 1234–1240.
19.
ParsonsCGStöfflerADanyszW. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system–too little activation is bad, too much is even worse. Neuropharmacology2007; 53: 699–723.
20.
SaitoTMatsubaYMihiraN, et al.Single App knock-in mouse models of Alzheimer’s disease. Nat Neurosci2014; 17: 661–663.
21.
MasudaAKobayashiYKogoN, et al.Cognitive deficits in single App knock-in mouse models. Neurobiol Learn Mem2016; 135: 73–82.
22.
ShahDLatif-HernandezADe StrooperB, et al.Spatial reversal learning defect coincides with hypersynchronous telencephalic BOLD functional connectivity in APPNL-F/NL-F knock-in mice. Sci Rep2018; 8: 6264.
23.
BritzJOjoEDhukhwaA, et al.Assessing sex-specific circadian, metabolic, and cognitive phenotypes in the AβPP/PS1 and APPNL-F/NL-F models of Alzheimer’s disease. J Alzheimers Dis2022; 85: 1077–1093.
24.
KunduPTorresERSStagamanK, et al.Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in App NL-G-F, App NL-F, and wild type mice. Sci Rep2021; 11: 4678.
25.
HascupKNHascupER. Altered neurotransmission prior to cognitive decline in AβPP/PS1 mice, a model of Alzheimer’s disease. J Alzheimers Dis2015; 44: 771–776.
26.
HascupKNRutherfordECQuinteroJE, et al. Second-by-second measures of L-glutamate and other neurotransmitters using enzyme-based microelectrode arrays. In: Electrochemical Methods for Neuroscience. Boca Raton (FL): CRC Press/Taylor & Francis, 2007, pp.407–450.
27.
RudyCCHunsbergerHCWeitznerDS, et al.The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer’s disease. Aging Dis2015; 6: 131–148.
28.
RevettTJBakerGBJhamandasJ, et al.Glutamate system, amyloid β peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci2013; 38: 6–23.
29.
Valladolid-AcebesIMerinoBPrincipatoA, et al.High-fat diets induce changes in hippocampal glutamate metabolism and neurotransmission. Am J Physiol Endocrinol Metab2012; 302: E396–E402.
PodcasyJLEppersonCN. Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clin Neurosci2016; 18: 437–446.
32.
LawsKRIrvineKGaleTM. Sex differences in cognitive impairment in Alzheimer’s disease. World J Psychiatry2016; 6: 54.
33.
HascupERSimeLNPeckMR, et al.Amyloid-β42 stimulated hippocampal lactate release is coupled to glutamate uptake. Sci Rep2022; 12: 2775.
34.
FerreiraSTKleinWL. The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease. Neurobiol Learn Mem2011; 96: 529–543.
35.
WilcoxKCLacorPNPittJ, et al.Aβ oligomer-induced synapse degeneration in Alzheimer’s disease. Cell Mol Neurobiol2011; 31: 939–948.
36.
HascupKNHascupER. Soluble amyloid-β42 stimulates glutamate release through activation of the α7 nicotinic acetylcholine receptor. J Alzheimers Dis2016; 53: 337–347.
37.
ZoltowskaKMMaesakoMMeierJ, et al. Novel interaction between Alzheimer’s disease-related protein presenilin 1 and glutamate transporter 1. Sci Rep2018; 8: 8718.
38.
WuBYamaguchiHLaiFA, et al.Presenilins regulate calcium homeostasis and presynaptic function via ryanodine receptors in hippocampal neurons. Proc Natl Acad Sci U S A2013; 110: 15091–15096.
39.
KuzuyaAZoltowskaKMPostKL, et al.Identification of the novel activity-driven interaction between synaptotagmin 1 and presenilin 1 links calcium, synapse, and amyloid beta. BMC Biol2016; 14: 25.
40.
VargaEJuhászGBozsóZ, et al.Amyloid-β1–42 disrupts synaptic plasticity by altering glutamate recycling at the synapse. J Alzheimers Dis2015; 45: 449–456.
41.
SheldonALRobinsonMB. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int2007; 51: 333–355.
42.
ChowenJAGarcia-SeguraLM. Role of glial cells in the generation of sex differences in neurodegenerative diseases and brain aging. Mech Ageing Dev2021; 196: 111473.
43.
SpencerJLWatersEMRomeoRD, et al.Uncovering the mechanisms of estrogen effects on hippocampal function. Front Neuroendocrinol2008; 29: 219–237.
44.
NematipourSVahidiniaZNejatiM, et al.Estrogen and progesterone attenuate glutamate neurotoxicity via regulation of EAAT3 and GLT-1 in a rat model of ischemic stroke. Iran J Basic Med Sci2020; 23: 1346–1352.
45.
WangYShangYMishraA, et al.Midlife chronological and endocrinological transitions in brain metabolism: system biology basis for increased Alzheimer’s risk in female brain. Sci Rep2020; 10: 8528.
46.
GeorgakisMKBeskou-KontouTTheodoridisI, et al.Surgical menopause in association with cognitive function and risk of dementia: a systematic review and meta-analysis. Psychoneuroendocrinology2019; 106: 9–19.
47.
MinkevicieneRIhalainenJMalmT, et al.Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J Neurochem2008; 105: 584–594.
48.
JiaoSSLeBXLiuYH, et al.Sex dimorphism profile of Alzheimer’s disease-type pathologies in an APP/PS1 mouse model. Neurotox Res2016; 29: 256–266.
49.
MazzeiGIkegamiRAbolhassaniN, et al.A high-fat diet exacerbates the Alzheimer’s disease pathology in the hippocampus of the app NL−F/NL−F knock-in mouse model. Aging Cell2021; 20: e13429.
50.
SalasIHCallaerts-VeghZD’HoogeR, et al.Increased insoluble amyloid-β induces negligible cognitive deficits in old APPNL/NL knock-in mice. J Alzheimers Dis2018; 66: 801–809.
51.
MielkeMM. Sex and gender differences in Alzheimer disease dementia. Psychiatr Times2018; 35: 14–15.
52.
AndreanoJMCahillL. Sex influences on the neurobiology of learning and memory. Learn Mem2009; 16: 248–266.
53.
GrissomNMReyesTM. Let’s call the whole thing off: evaluating gender and sex differences in executive function. Neuropsychopharmacology2019; 44: 86–96.
54.
GiacomettiLLBarkerJM. Sex differences in the glutamate system: implications for addiction. Neurosci Biobehav Rev2020; 113: 157–168.
55.
BarthCVillringerASacherJ. Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Front Neurosci2015; 9: 37.
56.
HädelSWirthCRappM, et al.Effects of age and sex on the concentrations of glutamate and glutamine in the human brain. J Magn Reson Imaging2013; 38: 1480–1487.
57.
HäggSJylhäväJ. Sex differences in biological aging with a focus on human studies. Elife2021; 10: e63425.
